Response to Comments: MolDX: Non-Next Generation Sequencing Tests for the Diagnosis of BCR-ABL Negative Myeloproliferative Neoplasms

This document is a response to comments for MolDX LCD L39923 concerning non-next-generation sequencing tests for diagnosing BCR-ABL-negative myeloproliferative neoplasms. It provides administrative timeline information (comment period: 2024-08-01 to 2024-09-15; notice begins 2025-07-03; effective 2025-08-17) and does not itself state clinical coverage criteria or limitations.

"Response-to-comments notice for MolDX LCD L39923 regarding non-NGS tests for diagnosis of BCR-ABL-negative myeloproliferative neoplasms; public comment period 2024-08-01 to 2024-09-15; notice perio..."

Sign up to see full coverage criteria, indications, and limitations.